[Treatment of schizophrenic psychoses with Lyorodin].
Forty-four patients suffering from acute and chronic schizophrenic psychoses were used to obtain, by using Lorr's scale (IMPS) and taking the changes in disease state observed within three months as a base, suggestions or pointers as to the proper treatment of disease with fluphenazine (lyorodin) which is a neuroleptically highly potent phenothiazine derivative. Megalomania, grandiose delusions apathetic and depressive syndromes showed marked tendencies toward major improvement. An "antiautistic" effect was observed in chronic patients. The effective dose was between 6 and 12 mg a day. The drug was well tolerated. In the majority of cases it was also necessary for antiparkinsonian drugs to be administered to patients. After twelve months of treatment, slight to major improvements or even freedom from symptoms could be observed in 28 cases (or 64%).
D000208:Acute Disease; D002908:Chronic Disease; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D012559:Schizophrenia / Q000188:drug therapy*; D012560:Schizophrenia, Catatonic / Q000188:drug therapy; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D013577:Syndrome
D005476:Fluphenazine
Die Behandlung mit Lyorodin bei schizophrenen Psychosen.